Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities

BACKGROUND: Chimeric antigen receptor (CAR) T cell immunotherapy has resulted in complete remission (CR) and durable response in highly refractory patients. However, logistical complexity and high costs of manufacturing autologous viral products limit CAR T cell availability. METHODS: We report the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Magnani, Chiara F., Gaipa, Giuseppe, Lussana, Federico, Belotti, Daniela, Gritti, Giuseppe, Napolitano, Sara, Matera, Giada, Cabiati, Benedetta, Buracchi, Chiara, Borleri, Gianmaria, Fazio, Grazia, Zaninelli, Silvia, Tettamanti, Sarah, Cesana, Stefania, Colombo, Valentina, Quaroni, Michele, Cazzaniga, Giovanni, Rovelli, Attilio, Biagi, Ettore, Galimberti, Stefania, Calabria, Andrea, Benedicenti, Fabrizio, Montini, Eugenio, Ferrari, Silvia, Introna, Martino, Balduzzi, Adriana, Valsecchi, Maria Grazia, Dastoli, Giuseppe, Rambaldi, Alessandro, Biondi, Andrea
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2020
Matèries:
Clinical Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7598053/
https://ncbi.nlm.nih.gov/pubmed/32780725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI138473
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars